Answers are grounded in this paper and cite their sources.
Cross-sectional study examines the link between serum adropin levels and cognitive function in the elderly, suggesting strong diagnostic potential.
Objective: Despite promising data from rodent models demonstrating a link between adropin deficiency and cognitive dysfunction, in-depth examinations of such an association in humans are lacking. Accordingly, the present study investigated the relationship between serum adropin levels and cognitive function in a sample of elderly individuals. Method: This cross-sectional study included 90 elderly (≥ 65 years of age) participants from geriatric outpatient clinics at Mansoura University (Mansoura City, Egypt), who were classified with normal cognition, mild neurocognitive disorder/mild cognitive impairment, or major neurocognitive disorder/dementia according to criteria from the Diagnostic and Statistical Manual of Psychiatric Disorders, Fifth Edition. Assessments included a comprehensive geriatric evaluation, cognitive testing, and measurement of serum adropin levels and metabolic parameters. Adropin levels ≤ 1.9 ng/mL yielded 90.2% sensitivity and 95.9% specificity for discriminating cognitive impairment (mild cognitive impairment and dementia), and ≤ 1.6 ng/mL specifically for dementia, with 83.3% sensitivity and 93.1% specificity. Conclusions: Lower serum adropin levels were significantly associated with cognitive impairment in elderly individuals, with strong diagnostic discriminative ability (area under the receiver operating characteristic curve, 0.993). However, larger-scale longitudinal studies are required to establish causality and validate these findings.
No takes yet. Share an insight, caveat, or question.
Abousamra et al. (2026) studied this question.
Synapse has enriched 8 closely related papers on similar clinical questions. Consider them for comparative context: